首页> 外文期刊>Biological & pharmaceutical bulletin >In Vitro/in Vivo Evaluation of Two Series of TA-5707F Controlled Release Matrix Tablets Prepared with Hydroxypropyl Methyl Cellulose Derivatives with Entero-Soluble or Gel-Formation Properties
【24h】

In Vitro/in Vivo Evaluation of Two Series of TA-5707F Controlled Release Matrix Tablets Prepared with Hydroxypropyl Methyl Cellulose Derivatives with Entero-Soluble or Gel-Formation Properties

机译:含肠溶性或凝胶形成特性的羟丙基甲基纤维素衍生物制备的两个TA-5707F控释基质片剂的体外/体内评价

获取原文
获取原文并翻译 | 示例

摘要

Two series of matrix tablets for the newly developed anti-histaminergic drug, TA-5707F, were prepared: one series with an entero-soluble polymer, hydroxypropylmethylcellulose acetyl succinate (HPMC-AS), and one series with a hydrophilic gel-forming polymer, hydroxypropylmethylcellulose (HPMC). In the JP dissolution test of HPMC-AS tablets, as the soluble-pH of HPMC-AS was increased, the dissolution of the drug in the JP XII second fluid (pH 6.8) was increasingly delayed, and the duration time of the constant plasma level in fasted dogs was increased. However, the absorption of TA-5707F in fed dogs was markedly diminished. In the JP dissolution test, the HPMC tablets showed a zero order dissolution profile, being the same in both the JP first (pH 1.2) and the JP second fluids. The H-2 tablet, containing HPMC 60SH-4000 and lactose, showed a constant plasma level in fasted dogs. However, this tablet was disintegrated by the ingestion of food. The H-3 tablet containing a lot of HPMC 60SH-4000, but not lactose, showed insufficient duration in fasted dogs, but its plasma profile was less affected by food, and the propantheline bromide pretreatment extended the constant plasma level in dogs. Thus, the H-3 tablets were considered promising for human use. Then, H-2 and H-3 tablets were administered to humans; however, the plasma concentration profiles did not show sufficient duration time for either tablet. TA-5707F was considered to have been released slowly in human gastro-intestinal (GI) tract due to more moderate GI mobility.
机译:制备了两套用于新开发的抗组胺药TA-5707F的基质片剂:一种含有肠溶性聚合物羟丙基甲基纤维素乙酰琥珀酸酯(HPMC-AS),另一种含有亲水性凝胶形成聚合物,羟丙基甲基纤维素(HPMC)。在HPMC-AS片剂的JP溶出度测试中,随着HPMC-AS的可溶pH值的增加,药物在JP XII第二液(pH 6.8)中的溶出度逐渐增加,并且恒定血浆的持续时间禁食犬的血脂水平升高。但是,TA-5707F在被喂食的狗中的吸收显着减少。在JP溶出度测试中,HPMC片剂显示出零级溶出曲线,在JP初液(pH 1.2)和JP第二液中相同。含有HPMC 60SH-4000和乳糖的H-2片剂在禁食狗中显示出恒定的血浆水平。但是,这种片剂因摄入食物而崩解。含有大量HPMC 60SH-4000但不含乳糖的H-3片剂在禁食的狗中显示持续时间不足,但其血浆特征受食物的影响较小,而溴代蒽环预处理可延长狗的恒定血浆水平。因此,H-3片剂被认为有希望用于人类。然后,将H-2和H-3片剂施用于人类;但是,血浆浓度曲线未显示任何片剂的足够持续时间。由于更适度的胃肠道活动性,TA-5707F被认为已在人的胃肠道(GI)中缓慢释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号